 Home > Active Ingredient News > Study of Nervous System > JNNP: The effect of Erenumab on functional outcomes in patients with paroxysmal migraine: the results of the LIBERTY study

JNNP: The effect of Erenumab on functional outcomes in patients with paroxysmal migraine: the results of the LIBERTY study

 Last Update: 2021-03-26
 Source: Internet
 Author: User

Tags

140 mg

6 mp drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Erenumab is a fully human monoclonal antibody that inhibits the classic calcitonin gene-related peptide (CGRP) receptor.

prevention

An important part of migraine treatment is to assess the headache-related functional impairment reported by the patient and measure it based on the patient-reported outcome (PRO).

The analysis is based on data from a Phase 3b, 12-week, randomized, double-blind, placebo-controlled, multi-center, parallel-group LIBERTY study conducted in 16 countries in Europe and Australia from March 20 to October 27, 2017, involving 2 -4 kinds of EM patients whose preventive drugs are ineffective.

Compared with placebo, Erenumab significantly improved physical impairment (PI) and daily activity (EA) scores (treatment difference (TD) (95% CI) migraine effect on physical function (MPFID)-PI: −3.

In summary, at 12 weeks, Erenumab is effective for functional outcomes in patients with EM who have failed 2-4 preventive measures.

Lanteri-MinetM ,GoadsbyPJ ,ReuterU Lanteri-MinetMLanteri-Minet GoadsbyPJGoadsby ReuterUReuter, et albmj.
com/content/early/2021/03/11/jnnp-2020-324396" target="_blank" rel="noopener">Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2–4 preventives were not useful: results from the LIBERTY studyJournal of Neurology, Neurosurgery & Psychiatry Published Online First:05 January 2021.
Published Online First: doi: 10.
1136/jnnp-2020-324396doi:leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Sodium bromide airuike

CAS No.: 7647-15-6

Industrial Grade

$10/KG EXW

Brivaracetam357336-20-0

CAS No.: 357336-20-0

API Grade

$100/KG EXW

Quetiapine fumarate CAS 111974-72-2

CAS No.: 111974-72-2

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.